A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2017
At a glance
- Drugs Pimavanserin (Primary)
- Indications Aggression; Agitation
- Focus Therapeutic Use
- Sponsors Acadia Pharmaceuticals
- 18 Apr 2017 Planned End Date changed from 19 Jan 2019 to 1 Jul 2019.
- 09 Mar 2016 New trial record
- 29 Feb 2016 According to an Acadia Pharmaceuticals media release, this trial is expected to start in the first half of 2016.